9P BRCA1 promoter methylation confers a more favorable prognosis to systemically untreated young triple-negative breast cancer patients than tumour BRCA1 mutation

2021 ◽  
Vol 32 ◽  
pp. S24-S25
Author(s):  
Y. Wang ◽  
E.H. Rosenberg ◽  
G.M.H.E. Dackus ◽  
A. Broeks ◽  
S. Cornelissen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Triple Negative Breast Cancer ◽  
Promoter Methylation ◽  
Triple Negative ◽  
Brca1 Mutation ◽  
Breast Cancer Patients ◽  
Brca1 Promoter ◽  
Favorable Prognosis ◽  
Brca1 Promoter Methylation

scholarly journals The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer

2014 ◽  
Vol 3 (1) ◽  
pp. 2 ◽  
Author(s):  
Priyanka Sharma ◽  
Shane R Stecklein ◽  
Bruce F Kimler ◽  
Geetika Sethi ◽  
Brian K Petroff ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Promoter Methylation ◽  
Prognostic Value ◽  
Triple Negative ◽  
Early Stage ◽  
Brca1 Promoter ◽  
Brca1 Promoter Methylation

scholarly journals BRCA1 promoter methylation in peripheral blood is associated with the risk of triple‐negative breast cancer

2019 ◽  
Vol 146 (5) ◽  
pp. 1293-1298 ◽  
Author(s):  
Karolina Prajzendanc ◽  
Paweł Domagała ◽  
Jolanta Hybiak ◽  
Janusz Ryś ◽  
Tomasz Huzarski ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Promoter Methylation ◽  
Peripheral Blood ◽  
Triple Negative ◽  
Brca1 Promoter ◽  
Brca1 Promoter Methylation

BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy

2020 ◽  
Vol 181 (2) ◽  
pp. 323-329
Author(s):  
Asuka Kawachi ◽  
Satoshi Yamashita ◽  
Eriko Okochi-Takada ◽  
Akihiro Hirakawa ◽  
Hitoshi Tsuda ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Combination Therapy ◽  
Cancer Patients ◽  
Promoter Methylation ◽  
Breast Cancer Patients ◽  
Brca1 Promoter ◽  
Brca1 Promoter Methylation
Sign in / Sign up

Export Citation Format

Share Document